US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Weight Loss Drugs

1,187.22

-78.3923-6.19%

Number of Gainers:- -

Number of Losers:7

Number of Flat:- -

PE:- -

High:1,265.63

Open:1,265.63

Low:1,184.67

Close:1,265.61

Loading ...

Eli Lilly (NYSE:LLY) Announces Positive Phase 2 Results For siRNA Therapy Amid 6% Quarterly Price Dip

Simply Wall St.

Pfizer (NYSE:PFE) Involved In Lawsuit Over US$45 Per Share Cerevel Acquisition

Simply Wall St.

Pfizer Faces Stock Slump Amidst Regulatory Challenges

Amgen (NasdaqGS:AMGN) Gains FDA Approval For UPLIZNA In Treating IgG4-Related Disease

Simply Wall St.

AMGN's Uplizna Gets FDA Nod for 2nd Rare Autoimmune Disease Indication

Is Novo Nordisk A/S (NVO) The Best Beaten Down Stock to Buy According to Analysts?

Pfizer Inc. (PFE) – Jim Cramer Declares: ‘Dead Money – Close the Casket!’

Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure

Amgen Says Uplizna Wins US FDA Approval for IgG4-related Disease

MT Newswires Live

11 Stocks to Buy After the Biotech Bloodbath -- Barrons.com

UK Stocks-Factors to watch on April 4

Novo Nordisk (NVO) Stock Moves -1.67%: What You Should Know

BRIEF-Amgen Uplizna Wholesale Acquisition Cost Or U.S. List Price Is $140,248.50 Per Dose (3 Vials)

Shares of Sangamo Therapeutics Rally on Licensing Deal With Eli Lilly

Amgen: Uplizna Wholesale Acquisition Cost or U.S. List Price Is $140,248.50 per Dose (3 Vials)

THOMSON REUTERS

FDA Approves Second Indication for Amgen's Immune System Treatment Uplizna

Amgen announces FDA approval of Uplizna

Uplizna® (Inebilizumab-Cdon) Is NOW the First and Only FDA-Approved Treatment for Igg4-Related Disease

THOMSON REUTERS

UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE

US FDA approves Amgen's Uplizna as first treatment for rare immune disorder

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4599/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4599","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","market":"US","secType":"PLATE","nameCN":"Weight Loss Drugs","latestPrice":1187.2208,"timestamp":1743796799999,"preClose":1265.6132,"halted":0,"volume":112196694,"delay":0,"changeRate":-0.06194,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-78.392334,"latestTime":"04-04 16:00:00 EDT","open":1265.6283,"high":1265.6283,"low":1184.6676,"amount":8269809103.223244,"amplitude":0.06397,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1744012800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":9.900824,"peRate":34.831447,"turnoverRate":0.010628,"increases":0,"decrements":7,"flats":0,"marketCap":1269631553952,"floatMarketCap":1188762743232},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","high":1265.6283,"amplitude":0.06397,"preClose":1265.6132,"low":1184.6676,"pbRate":"9.900824","latestPrice":1187.2208,"volume":112196694,"delay":0,"open":1265.6283,"prevYearClose":1305.0607,"prevWeekClose":1306.637,"prevMonthClose":1314.3724,"prevQuarterClose":1314.3724,"fiveDayClose":1306.637,"twentyDayClose":1432.6436,"sixtyDayClose":1300.3678,"secType":"PLATE","market":"US","turnoverRate":0.010628,"peRate":34.831447,"marketCap":1269631553952,"floatMarketCap":1188762743232,"timestamp":1743796799999,"nameCN":"Weight Loss Drugs"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4599\",,,,undefined,":{"bkCode":"BK4599","up":0,"down":7,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4599\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2525712809","title":"Eli Lilly (NYSE:LLY) Announces Positive Phase 2 Results For siRNA Therapy Amid 6% Quarterly Price Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=2525712809","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525712809?lang=en_us&edition=fundamental","pubTime":"2025-04-06 01:52","pubTimestamp":1743875545,"startTime":"0","endTime":"0","summary":"Eli Lilly has recently announced several developments, including positive Phase 2 results for their siRNA therapy lepodisiran and the expansion of their digital healthcare platform, LillyDirect, to support Alzheimer's patients. Despite these advancements, Eli Lilly's stock fell 6% in the last quarter. This movement came amid a broader market downturn, with substantial declines in major indices such as the Dow and S&P 500 due to escalating tariff issues and growing economic concerns. These market-wide pressures likely overshadowed the company's positive clinical and strategic updates, impacting Eli Lilly's share performance.We've discovered 2 risks for Eli Lilly (1 doesn't sit too well with us!) that you should be aware of before investing here.Get in touch with us directly. Alternatively, email editoria","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/eli-lilly-nyse-lly-announces-175225552.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1551013342.USD","LU2023250504.SGD","LU0466842654.USD","LU2468319806.SGD","LU0079474960.USD","LU2552382132.HKD","LU0689472784.USD","LU0354030511.USD","LU1064131342.USD","LU2461242641.AUD","LU1868837300.USD","LU2552382215.SGD","LU1868836591.USD","LU1814569148.SGD","LU1917777945.USD","SG9999018857.SGD","IE00B2B36J28.USD","LU2063271972.USD","LU2237438978.USD","SG9999015945.SGD","LU1093756325.SGD","LU1868836914.USD","LU0320765059.SGD","LU0109391861.USD","LU0289739699.SGD","LU2237443895.HKD","LLY","LU1035775433.USD","LU1720051108.HKD","LU1366192091.USD","BK4599","LU2237443382.USD","LU1988902786.USD","LU1712237335.SGD","LU2265009873.SGD","LU0882574055.USD","LU1280957306.USD","GB00BDT5M118.USD","SGXZ57979304.SGD","LU1623119135.USD","LU1720051017.SGD","NYSE","BK4007","LU0456855351.SGD","SG9999001176.SGD","LU0061475181.USD","LU1804176565.USD","SGXZ81514606.USD","LU0094547139.USD","LU1983299246.USD"],"gpt_icon":1},{"id":"2525714416","title":"Pfizer (NYSE:PFE) Involved In Lawsuit Over US$45 Per Share Cerevel Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2525714416","media":"Simply Wall St.","labels":["policyRegulatory","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525714416?lang=en_us&edition=fundamental","pubTime":"2025-04-06 01:41","pubTimestamp":1743874893,"startTime":"0","endTime":"0","summary":"In recent developments, a class action lawsuit was filed against Cerevel Therapeutics, Bain Capital Investors, and Pfizer, citing alleged securities violations related to Cerevel's stock offering. This legal issue may have influenced Pfizer's recent stock activity, where shares fell 9% over the past week. Additionally, broader market dynamics played a role, as major indices plunged amidst fears of a trade war with China, affecting investor sentiment and contributing to the general downturn. While Pfizer also received marketing authorization for its RSV vaccine in Europe, these positive news items were overshadowed by the pervasive market setbacks, driving the stock decline.We've spotted 3 possible red flags for Pfizer you should be aware of, and 2 of them make us uncomfortable.NYSE:PFE Revenue & Expenses Breakdown as at Apr 2025. Over the last year, Pfizer's total shareholder return, which includes share price and dividends, recorded an 8.44% decline. This figure underperformed both th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-nyse-pfe-involved-lawsuit-174133461.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0321505439.SGD","IE00B19Z3B42.SGD","LU1066053197.SGD","SG9999002224.SGD","LU0170899867.USD","LU1883839398.USD","BK4568","LU1894683348.USD","SG9999001176.SGD","SG9999011175.SGD","LU1894683264.USD","LU0985481810.HKD","BK4592","BK4581","BK4588","LU0234572021.USD","SG9999003800.SGD","SGXZ57979304.SGD","PFE","IE0002270589.USD","IE000M9KFDE8.USD","LU0306806265.USD","LU1023059063.AUD","LU0058720904.USD","NYSE","SG9999002232.USD","LU0456855351.SGD","LU0225284248.USD","LU1066051498.USD","BK4550","IE00BLSP4452.SGD","LU1057294990.SGD","BK4007","LU0868494617.USD","LU0289739699.SGD","LU0122379950.USD","BK4533","IE00BBT3K403.USD","BK4534","LU0225771236.USD","LU0321505868.SGD","IE00BLSP4239.USD","BK4599","BK4585","IE00B19Z3581.USD","LU0306807586.USD","SG9999001176.USD","SG9999013999.USD"],"gpt_icon":1},{"id":"2525713438","title":"Pfizer Faces Stock Slump Amidst Regulatory Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2525713438","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525713438?lang=en_us&edition=fundamental","pubTime":"2025-04-05 22:02","pubTimestamp":1743861776,"startTime":"0","endTime":"0","summary":"Pfizer ( ($PFE) ) has fallen by -9.35%. Read on to learn why. Pfizer’s stock has experienced a significant decline of 9.35% over the past week, ref...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/weekend-updates/pfizer-faces-stock-slump-amidst-regulatory-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/weekend-updates/pfizer-faces-stock-slump-amidst-regulatory-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1057294990.SGD","BK4534","LU1894683348.USD","SG9999002224.SGD","LU0321505868.SGD","BK4533","LU0306806265.USD","BK4599","LU0321505439.SGD","BK4588","LU1894683264.USD","BK4592","IE00BBT3K403.USD","LU0234572021.USD","BK4585","LU0225284248.USD","SG9999001176.SGD","SGXZ57979304.SGD","BK4550","LU1066051498.USD","SG9999001176.USD","LU0456855351.SGD","IE00BLSP4452.SGD","LU1023059063.AUD","LU1883839398.USD","SG9999003800.SGD","SG9999013999.USD","BK4007","LU0170899867.USD","LU0306807586.USD","LU0058720904.USD","BK4568","LU1066053197.SGD","IE000M9KFDE8.USD","IE00B19Z3B42.SGD","LU0225771236.USD","IE0002270589.USD","IE00B19Z3581.USD","PFE","LU0985481810.HKD","SG9999002232.USD","LU0289739699.SGD","LU0868494617.USD","BK4581","IE00BLSP4239.USD","SG9999011175.SGD","LU0122379950.USD"],"gpt_icon":0},{"id":"2525734871","title":"Amgen (NasdaqGS:AMGN) Gains FDA Approval For UPLIZNA In Treating IgG4-Related Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2525734871","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525734871?lang=en_us&edition=fundamental","pubTime":"2025-04-05 01:34","pubTimestamp":1743788064,"startTime":"0","endTime":"0","summary":"Amgen experienced a significant 18.62% price increase over the last quarter, coinciding with the recent FDA approval of UPLIZNA for treating Immunoglobulin G4-related disease . This approval, alongside the Breakthrough Therapy Designation granted by the FDA, reflects high unmet medical needs being addressed, which could have positively influenced investor sentiment. Despite broader market declines, including a 5% drop in the Nasdaq Composite due to trade tensions, Amgen's drug developments and clinical trial successes, like the promising results from the MITIGATE trial, likely bolstered investor confidence, contrasting with the market's general bearish trend.You should learn about the 5 weaknesses we've spotted with Amgen .NasdaqGS:AMGN Earnings Per Share Growth as at Apr 2025","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgen-nasdaqgs-amgn-gains-fda-173424312.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Amgen (NasdaqGS:AMGN) Gains FDA Approval For UPLIZNA In Treating IgG4-Related Disease","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4566","BK4534","LU2468319806.SGD","SG9999001440.SGD","LU1023059063.AUD","LU0109394709.USD","IE00BJJMRZ35.SGD","LU0320765992.SGD","BK4585","LU1061106388.HKD","IE00B2B36J28.USD","BK4588","LU1571399168.USD","BK4533","LU2242646821.SGD","LU0889565916.HKD","LU0058720904.USD","LU0289739699.SGD","BK4139","BK4581","LU2089984988.USD","BK4599","AMGN","LU2242652126.USD","IE00B4R5TH58.HKD","LU0122379950.USD","LU0868494617.USD","LU1057294990.SGD","IE00BFTCPJ56.SGD","LU2112291526.USD","IE00BJT1NW94.SGD","IE0009355771.USD","IE0002141913.USD","LU1983299246.USD"],"gpt_icon":0},{"id":"2525734293","title":"AMGN's Uplizna Gets FDA Nod for 2nd Rare Autoimmune Disease Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=2525734293","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525734293?lang=en_us&edition=fundamental","pubTime":"2025-04-05 01:10","pubTimestamp":1743786600,"startTime":"0","endTime":"0","summary":"Amgen AMGN announced that the FDA has approved its rare disease drug Uplizna  for a new indication. The regulatory body has now approved Uplizna for the treatment of adults living with immunoglobulin G4-related disease , a rare immune-mediated inflammatory condition. This marks the second approved indication for the drug.Uplizna is currently approved in the United States for treating adults with a rare autoimmune disease called neuromyelitis optica spectrum disorder.Following the nod, Uplizna became the first and only drug approved by the FDA for the treatment of IgG4-RD, a chronic disease with a significant unmet medical need.The FDA had previously granted a breakthrough therapy designation to Uplizna for the treatment of IgG4-RD.Year to date, shares of Amgen have rallied 18.9% compared with the industry’s rise of 1.2%.Uplizna's Nod for IgG4-RD Based on AMGN's MITIGATE Study. Some better-ranked stocks in the biotech sector are Jazz Pharmaceuticals, Inc. JAZZ, Dynavax Technologies Corp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgns-uplizna-gets-fda-nod-171000251.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2112291526.USD","IE00B2B36J28.USD","BK4566","BK4599","LU0109394709.USD","BK4588","JAZZ","IE00BN0W2W23.USD","LU2468319806.SGD","LU0889565916.HKD","AMGN","LU2242652126.USD","IE0002141913.USD","LU0122379950.USD","LU2089984988.USD","BK4139","BK4581","IE00BFTCPJ56.SGD","BK4534","IE0009355771.USD","LU1023059063.AUD","IE00BN0W2T93.GBP","LU1571399168.USD","BK4532","BK4007","DVAX","BK4533","LU0823416689.USD","LU0868494617.USD","LU1983299246.USD","IE00B4R5TH58.HKD","IE00BN0W2V16.EUR","LU0058720904.USD","IE00BJJMRZ35.SGD","KRYS","LU0289739699.SGD","SG9999001440.SGD","BK4585","LU1061106388.HKD","LU2242646821.SGD","LU0320765992.SGD","IE00BJT1NW94.SGD","LU1057294990.SGD"],"gpt_icon":0},{"id":"2524789787","title":"Is Novo Nordisk A/S (NVO) The Best Beaten Down Stock to Buy According to Analysts?","url":"https://stock-news.laohu8.com/highlight/detail?id=2524789787","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524789787?lang=en_us&edition=fundamental","pubTime":"2025-04-04 22:48","pubTimestamp":1743778100,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Best Beaten Down Stocks to Buy According to Analysts. In this article, we are going to take a look at where Novo Nordisk A/S  stands against other best beaten down stocks to buy according to analysts.JPMorgan released a market update where it highlighted the US Fed’s recent decision to keep the rates unchanged. Also, the US Fed decreased the growth forecasts and increased the near-term inflation expectations. The futures markets are pricing 2 interest rate cuts this year and a ~50% chance of the third cut. Jose Torres, Senior Economist at Interactive Brokers, believes that stocks are being impacted as slowdown worries continue to pressure the outlook for broader corporate earnings growth. According to him, investors continue to pile up shares in the defensive consumer staple, utilities, and healthcare segments and the real estate and energy areas.To list the 10 Best Beaten Down Stocks to Buy According to Analysts, we used a screener and shortlisted th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novo-nordisk-nvo-best-beaten-144820190.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1093756325.SGD","SH","BK4532","LU0154236417.USD","VOO","OEF","BK4504","OEX","IE00BKVL7J92.USD",".SPX","BK4581","BK4599","BK4534","IVV","BK4588","BK4585","BK4559","LU1093756168.USD","SPXU","BK4007","SPY","SSO","SDS","ESmain","IE00BZ1G4Q59.USD","NVO","BK4550"],"gpt_icon":1},{"id":"2524782992","title":"Pfizer Inc. (PFE) – Jim Cramer Declares: ‘Dead Money – Close the Casket!’","url":"https://stock-news.laohu8.com/highlight/detail?id=2524782992","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524782992?lang=en_us&edition=fundamental","pubTime":"2025-04-04 22:45","pubTimestamp":1743777929,"startTime":"0","endTime":"0","summary":"We recently published a list of Jim Cramer’s Lightning Round: 8 Stocks in Focus. In this article, we are going to take a look at where Pfizer Inc.  stands against other stocks that Jim Cramer discusses.Jim Cramer, host of Mad Money, discussed on Monday how investor sentiment surrounding tech stocks has shifted over the past three months. He pointed out that not long ago, tech was seen as the leader of the market. However, that is no longer the case. Cramer noted that he had hoped for a thriving AI infrastructure space.“Three months ago, I thought we could be in for all sorts of exciting new technology. We went out to that GTC conference with Jensen Huang, but so far this year AI has only evolved in the direction of lower stock prices.”READ ALSO:Jim Cramer Looked At These 23 Stocks RecentlyandJim Cramer Put These 16 Stocks Under a Microscope.Why are we interested in the stocks that hedge funds pile into?","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-inc-pfe-jim-cramer-144529049.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999001176.USD","LU0321505868.SGD","LU1894683348.USD","SGXZ57979304.SGD","BK4568","BK4599","BK4007","IE00BLSP4239.USD","IE00BLSP4452.SGD","LU0289739699.SGD","LU0868494617.USD","IE00B19Z3581.USD","LU0122379950.USD","LU0985481810.HKD","BK4592","BK4534","SG9999003800.SGD","LU1066051498.USD","LU0306807586.USD","LU0234572021.USD","SG9999013999.USD","BK4533","LU0170899867.USD","BK4588","BK4585","IE00BBT3K403.USD","LU0321505439.SGD","LU0456855351.SGD","LU1057294990.SGD","BK4550","LU1894683264.USD","SG9999011175.SGD","IE0002270589.USD","LU0058720904.USD","LU0225284248.USD","SG9999002232.USD","LU1066053197.SGD","SG9999002224.SGD","IE000M9KFDE8.USD","LU1023059063.AUD","LU0225771236.USD","LU0306806265.USD","IE00B19Z3B42.SGD","LU1883839398.USD","BK4581","SG9999001176.SGD","PFE"],"gpt_icon":1},{"id":"2524784382","title":"Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2524784382","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524784382?lang=en_us&edition=fundamental","pubTime":"2025-04-04 21:46","pubTimestamp":1743774360,"startTime":"0","endTime":"0","summary":"This week, the FDA approved Sanofi’s SNY hemophilia therapy, fitusiran, Novartis’ NVS Vanrafia for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy and the expanded use of AstraZeneca’s AZN blockbuster cancer drug, Imfinzi. J&J’s JNJ bankruptcy strategy to settle talc lawsuits failed for the third time. The European Commission approved Pfizer’s PFE respiratory syncytial virus vaccine, Abrysvo, for use in adults aged 18 through 59 years.Here's a recap of the week’s most important stories.Texas Court Rejects J&J’s Bankruptcy Attempt to End Talc Suits. A bankruptcy court in Texas rejected J&J’s proposed bankruptcy plan to settle claims related to its talc lawsuits for the third time. In September, J&J, via a subsidiary called Red River Talc, filed for voluntary bankruptcy in the Southern District of Texas after it received the support of around 83% of current claimants for the proposed bankruptcy plan, which was above the 75% required by the U.S. bankruptcy","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pharma-stock-roundup-fda-nod-134600557.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","LU1732799900.SGD","LU0225284248.USD","LU2430703178.SGD","IE00BJT1NW94.SGD","IE00BLSP4239.USD","LU2592432038.USD","LU1280957306.USD","LU1894683264.USD","LU1244550221.USD","LU0320765992.SGD","LU1267930813.SGD","LU2112291526.USD","LU0345770993.USD","LU2602419157.SGD","IE00B2B36J28.USD","BK4533","BK4532","LU0345770308.USD","LU0868494617.USD","LU0070302665.USD","JNJ","AZN","IE00B1BXHZ80.USD","PFE","LU0114720955.EUR","LU1430594728.SGD","LU2133065610.SGD","LU2129689431.USD","LU1585245621.USD","NVS","LU0889566641.SGD","SG9999001440.SGD","BK4599","CHMP","LU2129689605.HKD","SG9999013999.USD","LU1674673691.USD","LU1778281490.HKD","IE00B3PB1722.GBP","LU0306807586.USD","IE00BSNM7G36.USD","LU0912757837.SGD","LU1261432733.SGD","IE00BVYPNW00.USD","LU0985320562.USD","SG9999001176.USD","SNY","LU0289739699.SGD","LU0058720904.USD"],"gpt_icon":1},{"id":"2524206201","title":"Amgen Says Uplizna Wins US FDA Approval for IgG4-related Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2524206201","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524206201?lang=en_us&edition=fundamental","pubTime":"2025-04-04 20:20","pubTimestamp":1743769202,"startTime":"0","endTime":"0","summary":"Amgen  said Friday the US Food and Drug Administration approved Uplizna as treatment for adults with immunoglobulin G4-related disease, a chronic immune-mediated inflammatory condition that can damage multiple organs.The company said the FDA's decision was supported by results from a randomized double-blind trial, which showed the drug significantly lowered the risk of disease flares compared with placebo, the company said.This is the second approved indication for Uplizna, which was already approved for the treatment of neuromyelitis optica spectrum disorder, Amgen said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4139","LU2089984988.USD","IE00BJT1NW94.SGD","LU2242652126.USD","LU1061106388.HKD","LU1057294990.SGD","BK4581","IE0009355771.USD","AMGN","BK4566","LU0320765992.SGD","LU2112291526.USD","IE00B2B36J28.USD","BK4533","LU0868494617.USD","BK4534","IE00BJJMRZ35.SGD","LU0122379950.USD","LU0889565916.HKD","LU1983299246.USD","BK4588","IE00B4R5TH58.HKD","IE0002141913.USD","LU1023059063.AUD","LU0109394709.USD","IE00BFTCPJ56.SGD","SG9999001440.SGD","BK4599","LU1571399168.USD","LU2468319806.SGD","LU2242646821.SGD","LU0289739699.SGD","LU0058720904.USD"],"gpt_icon":0},{"id":"2524224602","title":"11 Stocks to Buy After the Biotech Bloodbath -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2524224602","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524224602?lang=en_us&edition=fundamental","pubTime":"2025-04-04 13:00","pubTimestamp":1743742800,"startTime":"0","endTime":"0","summary":"Biotechnology may be the stuff that dreams are made of, but more recently, the sector has been a nightmare for investors.Biotech is coming off one of its worst weeks in several years after the SPDR S&P Biotech exchange-traded fund fell about 7% following the resignation of a key Food and Drug Administration regulator, Peter Marks, who oversaw approval processes for vaccines and novel biotech therapies. There were also fresh budget cuts at the agency and the departure of other drug regulators. It didn't help that the Trump administration's top health official, Robert F. Kennedy Jr, is a vaccine skeptic and lukewarm on traditional medicine.Even though they continue to lead the world in innovation, American companies face a growing threat from Chinese biotechs that have stron","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","LU1894683264.USD","VRTX","LU2242646821.SGD","LU0225771236.USD","LU2362540622.SGD","IE00BJJMRZ35.SGD","LU1929549753.HKD","LU1934455277.USD","LU0058720904.USD","IE00B19Z3B42.SGD","IE000M9KFDE8.USD","IE00B894F039.SGD","IE00BLSP4239.USD","LU0211331839.USD","LU1023059063.AUD","BK4585","LU1699723380.USD","IE00BJT1NW94.SGD","MRK","BK4578","LU0234570918.USD","LU0889565916.HKD","AMGN","LU1917777945.USD","LU0985320562.USD","LU0266013472.USD","LU1069347547.HKD","LU1116320737.USD","LU0306807586.USD","BK4588","LU2242652126.USD","LU0208291251.USD","LU1061106388.HKD","IE00B3T34201.USD","BK4599","IE00B2B36J28.USD","LU2417539215.USD","SG9999003800.SGD","BK4568","SG9999001176.SGD","GILD","LU0965509101.SGD","BK4533","LU0868494617.USD","LU2361044865.SGD","SG9999015341.SGD","LU2106854487.HKD","IE00BBT3K403.USD"],"gpt_icon":1},{"id":"2524210172","title":"UK Stocks-Factors to watch on April 4","url":"https://stock-news.laohu8.com/highlight/detail?id=2524210172","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524210172?lang=en_us&edition=fundamental","pubTime":"2025-04-04 12:51","pubTimestamp":1743742307,"startTime":"0","endTime":"0","summary":"UK Stocks-Factors to watch on April 4 April 4 - Britain's FTSE 100 .FTSE index is seen opening down on Friday, with futures FFIc1 down 0.28%.* RIO TINTO: An Australian mining union said it secured key","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250404:nL3N3QI07W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIP","BK7095","LU1489326972.SGD","LU0433182093.SGD","LU1035773651.USD","LU0162691827.USD","IE00BWDBJ516.SGD","LU0545562505.USD","LU0792757196.USD","RIO.UK","LU0368265418.SGD","LU0788109121.HKD","GLEN.UK","LU0211331839.USD","LU2360032135.SGD","LU0708994859.HKD","BK4585","LU0985481810.HKD","LU0211327993.USD","LU1829250122.USD","PFE","BHP.AU","LU0955669360.SGD","LU0971552673.USD","RIO.AU","LU0306807586.USD","SG9999002232.USD","BK7507","GSK.UK","LU1894683348.USD","LU0878866978.SGD","ICGT.UK","LU2125154935.USD","BK4599","SG9999013999.USD","IE0034235071.USD","BK4550","LU1019634622.SGD","LU1934455194.USD","BN","SHEL.UK","LU0612318971.USD","LU0052756011.USD","LU1400636491.USD","LU0068578508.USD","LU0965509101.SGD","LU1267930227.SGD","LU1934455863.HKD","BK4534","IE00BBT3K403.USD"],"gpt_icon":1},{"id":"2524106502","title":"Novo Nordisk (NVO) Stock Moves -1.67%: What You Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2524106502","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524106502?lang=en_us&edition=fundamental","pubTime":"2025-04-04 05:45","pubTimestamp":1743716714,"startTime":"0","endTime":"0","summary":"Novo Nordisk  ended the recent trading session at $67.10, demonstrating a -1.67% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily loss of 4.84%. Elsewhere, the Dow lost 3.98%, while the tech-heavy Nasdaq lost 5.97%.Prior to today's trading, shares of the drugmaker had lost 24.9% over the past month. This has lagged the Medical sector's loss of 4.6% and the S&P 500's loss of 4.7% in that time.Analysts and investors alike will be keeping a close eye on the performance of Novo Nordisk in its upcoming earnings disclosure. The company is predicted to post an EPS of $0.92, indicating a 10.84% growth compared to the equivalent quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $11.33 billion, up 19.06% from the prior-year quarter.In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $3.86 per share and a revenue of $49.71 billion, indicating changes of +17.68% and +18.0","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novo-nordisk-nvo-stock-moves-214514258.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4599","BK4585","BK4588","BK4532","LU1093756325.SGD","LU0154236417.USD","NVO","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","BK4007","LU1093756168.USD"],"gpt_icon":1},{"id":"2524321438","title":"BRIEF-Amgen Uplizna Wholesale Acquisition Cost Or U.S. List Price Is $140,248.50 Per Dose (3 Vials)","url":"https://stock-news.laohu8.com/highlight/detail?id=2524321438","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524321438?lang=en_us&edition=fundamental","pubTime":"2025-04-04 05:40","pubTimestamp":1743716430,"startTime":"0","endTime":"0","summary":"BRIEF-Amgen Uplizna Wholesale Acquisition Cost Or U.S. List Price Is $140,248.50 Per Dose April 3  - Amgen Inc AMGN.O:AMGEN: UPLIZNA WHOLESALE ACQUISITION COST OR U.S. LIST PRICE IS $140,248.50 PER DOSE Source text: [ID:]Further company coverage: AMGN.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nFWN3QH19T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN","BK4581","IE0009355771.USD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU0058720904.USD","LU2242646821.SGD","LU1983299246.USD","LU0122379950.USD","LU1057294990.SGD","BK4566","IE00BFTCPJ56.SGD","LU0889565916.HKD","LU2468319806.SGD","BK4534","IE0002141913.USD","LU0320765992.SGD","LU0289739699.SGD","LU0109394709.USD","LU1023059063.AUD","BK4533","BK4585","LU2089984988.USD","LU2112291526.USD","BK4588","LU1571399168.USD","BK4599","IE00BJJMRZ35.SGD","LU0868494617.USD","IE00B4R5TH58.HKD","SG9999001440.SGD","LU2242652126.USD","LU1061106388.HKD","BK4139"],"gpt_icon":0},{"id":"2524321657","title":"Shares of Sangamo Therapeutics Rally on Licensing Deal With Eli Lilly","url":"https://stock-news.laohu8.com/highlight/detail?id=2524321657","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524321657?lang=en_us&edition=fundamental","pubTime":"2025-04-04 04:45","pubTimestamp":1743713100,"startTime":"0","endTime":"0","summary":"Shares of Sangamo Therapeutics climbed after the genomic medicine company entered a licensing agreement with Eli Lilly for STAC-BBB.The stock rose 31% to 81 cents on volume of 3.1 million shares in after-hours trading Thursday. Shares ended the day's regular session down 4.7% at 62 cents, and have fallen 39% this year.The deal will see Lilly receive rights to employ Sangamo's proprietary capsid for up to five potential disease targets.Under the terms of the deal, Sangamo will receive $18 million as an upfront license fee, and is eligible to receive up to $1.4 billion in additional license fees, milestone payments, and tiered royalties, the companies said.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0385154629.USD","SG9999017495.SGD","LU0823416689.USD","LU0672654240.SGD","LU0320765059.SGD","LU1548497426.USD","LU2461242641.AUD","LU1267930730.SGD","LU1064131342.USD","LU1069344957.HKD","LU1868836914.USD","LU0417517546.SGD","LU0471298777.SGD","LENZ","LU0708995401.HKD","LU2265009873.SGD","LU0198837287.USD","LU1023059063.AUD","LU1989771016.USD","IE00B2B36J28.USD","BK4139","SG9999015945.SGD","LU1868837136.USD","IE00B1BXHZ80.USD","LU1868836757.USD","BK4599","SG9999015952.SGD","LLY","LU1917777945.USD","LU0882574139.USD","LU2360106947.USD","LU2602419157.SGD","BK4588","LU0466842654.USD","LU1988902786.USD","LU2468319806.SGD","BK4585","SG9999015978.USD","LU0114720955.EUR","LU0058720904.USD","LU2491049909.HKD","SG9999018857.SGD","LU1804176565.USD","LU2237443978.SGD","LU1035775433.USD","SGXZ31699556.SGD","SGMO","SG9999001176.SGD","SG9999014880.SGD","LU1983299246.USD"],"gpt_icon":0},{"id":"2524213681","title":"Amgen: Uplizna Wholesale Acquisition Cost or U.S. List Price Is $140,248.50 per Dose (3 Vials)","url":"https://stock-news.laohu8.com/highlight/detail?id=2524213681","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524213681?lang=en_us&edition=fundamental","pubTime":"2025-04-04 04:13","pubTimestamp":1743711203,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nFWN3QH19T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4599","LU2112291526.USD","LU1983299246.USD","LU0868494617.USD","BK4581","IE0009355771.USD","LU0320765992.SGD","LU1057294990.SGD","BK4533","AMGN","LU0122379950.USD","LU1571399168.USD","BK4585","LU2468319806.SGD","LU2242646821.SGD","IE00BFTCPJ56.SGD","LU0109394709.USD","IE00B4R5TH58.HKD","BK4534","BK4566","BK4588","LU1061106388.HKD","LU1023059063.AUD","IE0002141913.USD","IE00BJT1NW94.SGD","LU2089984988.USD","LU0289739699.SGD","IE00BJJMRZ35.SGD","LU2242652126.USD","SG9999001440.SGD","IE00B2B36J28.USD","LU0889565916.HKD","LU0058720904.USD"],"gpt_icon":0},{"id":"2524213504","title":"FDA Approves Second Indication for Amgen's Immune System Treatment Uplizna","url":"https://stock-news.laohu8.com/highlight/detail?id=2524213504","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524213504?lang=en_us&edition=fundamental","pubTime":"2025-04-04 04:10","pubTimestamp":1743711000,"startTime":"0","endTime":"0","summary":"Amgen said the Food and Drug Administration approved Uplizna for Immunoglobulin G4-related disease, the second approved indication.The biotechnology company said Thursday the FDA granted breakthrough therapy designation.In 2020, the FDA approved Uplizna for AQP4-IgG+ Neuromyelitis Optica Spectrum Disorder.Amgen is also working toward approval for generalized myasthenia gravis.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"FDA Approves Second Indication for Amgen's Immune System Treatment Uplizna","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1571399168.USD","BK4599","IE0009355771.USD","IE0002141913.USD","IE00BJT1NW94.SGD","LU0289739699.SGD","LU0868494617.USD","IE00BJJMRZ35.SGD","LU0122379950.USD","LU2468319806.SGD","LU2089984988.USD","IE00B4R5TH58.HKD","SG9999001440.SGD","LU2242652126.USD","BK4534","IE00BFTCPJ56.SGD","AMGN","LU0889565916.HKD","BK4533","LU1983299246.USD","BK4588","LU0320765992.SGD","LU1061106388.HKD","BK4585","IE00B2B36J28.USD","LU1057294990.SGD","BK4566","LU0109394709.USD","LU0058720904.USD","LU1023059063.AUD","LU2112291526.USD","LU2242646821.SGD","BK4139","BK4581"],"gpt_icon":1},{"id":"2524189422","title":"Amgen announces FDA approval of Uplizna","url":"https://stock-news.laohu8.com/highlight/detail?id=2524189422","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524189422?lang=en_us&edition=fundamental","pubTime":"2025-04-04 03:40","pubTimestamp":1743709212,"startTime":"0","endTime":"0","summary":"Amgen (AMGN) announced that the U.S. FDA has approved Uplizna as the first and only treatment for adults living with Immunoglobulin G4-related dise...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amgen-announces-fda-approval-of-uplizna?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amgen-announces-fda-approval-of-uplizna?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1057294990.SGD","BK4534","IE00B4R5TH58.HKD","LU0320765992.SGD","BK4533","IE00BJJMRZ35.SGD","LU2242646821.SGD","BK4599","SG9999001440.SGD","BK4588","LU0889565916.HKD","BK4566","BK4585","LU2112291526.USD","LU1571399168.USD","IE0002141913.USD","LU1023059063.AUD","LU1983299246.USD","LU2089984988.USD","LU2468319806.SGD","LU2242652126.USD","AMGN","IE00B2B36J28.USD","LU0058720904.USD","LU0109394709.USD","IE0009355771.USD","IE00BJT1NW94.SGD","LU0289739699.SGD","LU0868494617.USD","LU1061106388.HKD","BK4581","BK4139","LU0122379950.USD","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"2524601290","title":"Uplizna® (Inebilizumab-Cdon) Is NOW the First and Only FDA-Approved Treatment for Igg4-Related Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2524601290","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524601290?lang=en_us&edition=fundamental","pubTime":"2025-04-04 03:35","pubTimestamp":1743708904,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nTUA56PL5S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4533","SG9999001440.SGD","IE00B2B36J28.USD","LU0289739699.SGD","BK4139","LU2242652126.USD","LU0109394709.USD","LU0122379950.USD","LU1061106388.HKD","BK4534","LU0058720904.USD","LU2242646821.SGD","BK4585","BK4566","BK4581","LU1571399168.USD","BK4588","LU0889565916.HKD","AMGN","IE0009355771.USD","IE00BFTCPJ56.SGD","LU0868494617.USD","IE00BJT1NW94.SGD","LU1023059063.AUD","BK4599","IE0002141913.USD","LU0320765992.SGD","LU2468319806.SGD","IE00BJJMRZ35.SGD","LU1983299246.USD","LU1057294990.SGD","LU2112291526.USD","LU2089984988.USD","IE00B4R5TH58.HKD"],"gpt_icon":0},{"id":"2524182362","title":"UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE","url":"https://stock-news.laohu8.com/highlight/detail?id=2524182362","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524182362?lang=en_us&edition=fundamental","pubTime":"2025-04-04 03:35","pubTimestamp":1743708900,"startTime":"0","endTime":"0","summary":"Breakthrough CD19+ B-Cell Targeted Therapy Delivered an 87% Reduction in the Risk of Flares Versus Placebo. UPLIZNA Shown to Deliver Corticosteroid-Free, Flare-Free, Complete Remission for Patients in the MITIGATE Trial. Advances Amgen's Leadership in CD19 Directed, B-Cell Depletion Therapies for Serious Autoimmune Diseases Including NMOSD,IgG4-RD and gMG. THOUSAND OAKS, Calif., April 3, 2025 /PRNewswire/ -- Amgen  announced today that the U.S. Food and Drug Administration  has approved UPLIZNA as the first and only treatment for adults living with Immunoglobulin G4-related disease . IgG4-RD is a chronic and debilitating immune-mediated inflammatory condition that can affect multiple organs. The FDA granted Breakthrough Therapy Designation to UPLIZNA for the treatment of IgG4-RD, recognizing the high unmet medical need in this serious condition and the medicine's potential to benefit patients.The approval of UPLIZNA for IgG4-RD is supported by data from the MITIGATE trial, the first ra","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/uplizna-inebilizumab-cdon-now-first-193500981.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/uplizna-inebilizumab-cdon-now-first-193500981.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4503","LU0348723411.USD","LU1803068979.SGD","LU0672654240.SGD","BK4139","LU1951200564.SGD","BK4608","BK4097","BK4528","LU1057294990.SGD","LU1061106388.HKD","BK4613","LU1551013425.SGD","AMGN","LU2125909247.SGD","LU2286300806.USD","LU0353189680.USD","IS","LU0889565833.HKD","NOW","LU1323610961.USD","LU1917777945.USD","LU2023250843.SGD","LU0889565916.HKD","BK4534","LU1983299246.USD","LU2087625088.SGD","IE00B4R5TH58.HKD","LU0943347566.SGD","IE0002141913.USD","LU1551013342.USD","IE00BMPRXN33.USD","LU1988902786.USD","BK4599","LU0265550359.USD","FOR","LU0316494557.USD","LU0689472784.USD","PML","LU0320765059.SGD","LU1989764748.USD","LU2468319806.SGD","BK4543","BK4607","LU0265550946.USD","LU0708995401.HKD","LU0289739699.SGD","LU0058720904.USD","LU2458330243.SGD"],"gpt_icon":0},{"id":"2524297808","title":"US FDA approves Amgen's Uplizna as first treatment for rare immune disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2524297808","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524297808?lang=en_us&edition=fundamental","pubTime":"2025-04-04 02:56","pubTimestamp":1743706592,"startTime":"0","endTime":"0","summary":"UPDATE 3-US FDA approves Amgen's Uplizna as first treatment for rare immune disorderAdds pricing details in paragraph 4By Deena Beasley, Mariam Sunny and Siddhi MahatoleApril 3 (Reuters) - The U.S. Fo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nL3N3QH1SF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","BK4534","LU2468319806.SGD","SG9999001440.SGD","LU1023059063.AUD","LU0109394709.USD","IE00BJJMRZ35.SGD","LU0320765992.SGD","BK4585","LU1061106388.HKD","IE00B2B36J28.USD","BK4588","LU1571399168.USD","BK4533","LU2242646821.SGD","LU0889565916.HKD","LU0058720904.USD","LU0289739699.SGD","BK4139","BK4581","LU2089984988.USD","BK4599","AMGN","LU2242652126.USD","IE00B4R5TH58.HKD","LU0122379950.USD","LU0868494617.USD","LU1057294990.SGD","IE00BFTCPJ56.SGD","LU2112291526.USD","IE00BJT1NW94.SGD","IE0009355771.USD","IE0002141913.USD","LU1983299246.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":1,"totalSize":154}]}}